Detailed Analysis of the Scope and Claims of United States Patent 10,414,831
Introduction
The United States Patent 10,414,831, titled "Stable Iron Oligosaccharide Compound," is a significant development in the treatment of iron deficiency anemia. This patent, assigned to Pharmacosmos Holding A/S, was issued on September 17, 2019, and is credited to inventor Hans Andreasen. Here is a detailed analysis of its scope, claims, and the broader patent landscape.
Patent Overview
Invention Description
The patent describes a stable iron oligosaccharide compound that comprises a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide. A key characteristic of this compound is that the content of dimer saccharide in the hydrogenated oligosaccharide is 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide[2][4].
Use in Iron Deficiency Anemia
The compound is specifically designed for the treatment of iron deficiency anemia. This condition is a common health issue worldwide, and the development of stable and effective iron formulations is crucial for its management.
Scope of the Patent
Claims
The patent includes 30 claims that define the scope of the invention. These claims cover various aspects, including:
- The composition of the iron oligosaccharide compound.
- The process for preparing the compound.
- The use of the compound in compositions for treating iron deficiency anemia.
- Specific parameters such as the content of dimer saccharide and the stability of the compound[4].
Independent and Dependent Claims
The claims are structured to include both independent and dependent claims. Independent claims define the broad scope of the invention, while dependent claims narrow down the scope by adding specific details or limitations. For example, Claim 1 might describe the general composition of the iron oligosaccharide compound, while subsequent claims might specify the exact percentage of dimer saccharide or the method of preparation[3].
Patent Claims Analysis
Claim Length and Count
Research on patent scope suggests that the length and count of independent claims can be indicative of the patent's breadth and complexity. In this case, the 30 claims indicate a detailed and specific definition of the invention, which helps in maintaining clarity and reducing the risk of overly broad claims[3].
Process for Preparation
The patent includes claims related to the process of preparing the stable iron oligosaccharide compound. This ensures that the method of production is protected, which is crucial for maintaining the quality and consistency of the final product[4].
Patent Landscape
Related Patents
There are several related patents that complement or build upon the invention described in US 10,414,831. For instance:
- US 8,815,301: This patent, also by Hans Andreasen and assigned to Pharmacosmos Holding A/S, describes a similar iron oligosaccharide compound with improved stability. It was issued on August 26, 2014, and has a patent expiration date of August 14, 2029[2].
- US 11,633,489 and US 11,851,504: These patents, with expiration dates in 2036 and 2029 respectively, further expand on the technology related to iron oligosaccharide compounds[2].
Patent Expiration Dates
The patent US 10,414,831 is set to expire on March 25, 2029. This expiration date is significant as it marks the end of the exclusive rights granted to the patent holder, after which the technology can be used by others without infringement[2].
International and Foreign Patent Documents
The patent has been filed and granted in various jurisdictions, including India, where it was granted as Indian Patent No. 291100 on December 13, 2018. This global coverage ensures that the invention is protected across multiple markets[1][4].
Practical Implications
Treatment of Iron Deficiency Anemia
The stable iron oligosaccharide compound has practical implications for the treatment of iron deficiency anemia. Its stability and specific formulation make it a reliable option for patients, reducing the risk of adverse reactions and improving the efficacy of treatment.
Manufacturing and Licensing
The detailed process claims and the specific composition claims help in standardizing the manufacturing process. This can facilitate licensing agreements and collaborations with other pharmaceutical companies, ensuring widespread availability of the treatment.
Key Takeaways
- Stable Iron Oligosaccharide Compound: The patent describes a compound with improved stability, comprising a hydrogenated oligosaccharide and ferric oxyhydroxide.
- Claims and Scope: The patent includes 30 claims that define the composition, preparation process, and use of the compound.
- Related Patents: Several related patents expand on the technology, ensuring comprehensive protection.
- Patent Expiration: The patent expires on March 25, 2029, marking the end of exclusive rights.
- Global Protection: The patent is protected in multiple jurisdictions, including India.
FAQs
Q: What is the main invention described in US Patent 10,414,831?
A: The main invention is a stable iron oligosaccharide compound for treating iron deficiency anemia.
Q: Who is the inventor and assignee of the patent?
A: The inventor is Hans Andreasen, and the assignee is Pharmacosmos Holding A/S.
Q: What is the significance of the dimer saccharide content in the compound?
A: The dimer saccharide content must be 2.9% by weight or less to ensure the stability of the compound.
Q: When does the patent expire?
A: The patent expires on March 25, 2029.
Q: Are there related patents that complement this invention?
A: Yes, there are several related patents, including US 8,815,301 and others, that expand on the technology.
Sources
- United States Patent and Trademark Office - US10865255.pdf
- Drugs.com - Generic Monoferric Availability
- SSRN - Patent Claims and Patent Scope
- United States Patent and Trademark Office - US10414831.pdf
- Google Patents - US7754702B2 - Methods and compositions for administration of iron
